Baidu
map

《中成药治疗年龄相关性黄斑变性(湿性)临床应用指南(2020年)》解读

2022-03-28 北京中医药大学 中国中医眼科杂志

中成药在湿性年龄相关性黄斑变性(wAMD)的治疗中应用广泛,但我国目前尚缺乏用于指导中成药治疗wAMD的规范化使用方案,存在临床不合理用药的隐忧。2020年《中成药治疗优势病种临床应用指南》标准化项目

中文标题:

《中成药治疗年龄相关性黄斑变性(湿性)临床应用指南(2020年)》解读

发布机构:

北京中医药大学

发布日期:

2022-03-28

简要介绍:

中成药在湿性年龄相关性黄斑变性(wAMD)的治疗中应用广泛,但我国目前尚缺乏用于指导中成药治疗wAMD的规范化使用方案,存在临床不合理用药的隐忧。2020年《中成药治疗优势病种临床应用指南》标准化项目组正式发布了《中成药治疗年龄相关性黄斑变性(湿性)临床应用指南(2020年)》。本指南以“循证为主,共识为辅,经验为鉴”为指导原则,通过文献检索研究、专家共识讨论、患者意见征询等工作,针对中成药治疗w AMD临床过程中的主要临床问题,就中成药对结局指标的临床疗效、安全性、使用方法及推荐强度等形成3条推荐意见。本文将主要对指南制订背景、研究方法及推荐意见形成过程进行介绍,以期能帮助指南更好地指导临床实践。

相关资料下载:
[AttachmentFileName(sort=1, fileName=《中成药治疗年龄相关性黄斑变性(湿性)临床应用指南(2020年)》解读.pdf)] GetToolGuiderByIdResponse(projectId=1, id=658e61c002a03917, title=《中成药治疗年龄相关性黄斑变性(湿性)临床应用指南(2020年)》解读, enTitle=, guiderFrom=中国中医眼科杂志, authorId=0, author=, summary=中成药在湿性年龄相关性黄斑变性(wAMD)的治疗中应用广泛,但我国目前尚缺乏用于指导中成药治疗wAMD的规范化使用方案,存在临床不合理用药的隐忧。2020年《中成药治疗优势病种临床应用指南》标准化项目, cover=https://img.medsci.cn/20220403/1649000369492_5579292.png, journalId=0, articlesId=null, associationId=2302, associationName=北京中医药大学, associationIntro=北京中医药大学, copyright=0, guiderPublishedTime=Mon Mar 28 00:00:00 CST 2022, originalUrl=, linkOutUrl=, content=<p><span style="color: #666666;">中成药在湿性年龄相关性黄斑变性(wAMD)的治疗中应用广泛,但我国目前尚缺乏用于指导中成药治疗wAMD的规范化使用方案,存在临床不合理用药的隐忧。2020年《中成药治疗优势病种临床应用指南》标准化项目组正式发布了《中成药治疗年龄相关性黄斑变性(湿性)临床应用指南(2020年)》。本指南以&ldquo;循证为主,共识为辅,经验为鉴&rdquo;为指导原则,通过文献检索研究、专家共识讨论、患者意见征询等工作,针对中成药治疗w AMD临床过程中的主要临床问题,就中成药对结局指标的临床疗效、安全性、使用方法及推荐强度等形成3条推荐意见。本文将主要对指南制订背景、研究方法及推荐意见形成过程进行介绍,以期能帮助指南更好地指导临床实践。 <!-- pagebreak --></span></p>, tagList=[TagDto(tagId=1788, tagName=黄斑变性), TagDto(tagId=9028, tagName=年龄相关性黄斑变性)], categoryList=[CategoryDto(categoryId=32, categoryName=眼科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=解读, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=20106, appHits=84, showAppHits=0, pcHits=458, showPcHits=20022, likes=1, shares=13, comments=4, approvalStatus=1, publishedTime=Mon Apr 04 15:38:00 CST 2022, publishedTimeString=2022-03-28, pcVisible=1, appVisible=1, editorId=0, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=FUNNYMAN, createdTime=Sun Apr 03 23:41:40 CST 2022, updatedBy=5579292, updatedName=FUNNYMAN, updatedTime=Thu Jan 04 01:48:14 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=《中成药治疗年龄相关性黄斑变性(湿性)临床应用指南(2020年)》解读.pdf)])
《中成药治疗年龄相关性黄斑变性(湿性)临床应用指南(2020年)》解读.pdf
下载请点击:
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1220566, encodeId=fc1f1220566ad, content=受益, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44565409552, createdName=眼科芳, createdTime=Tue May 17 23:11:35 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212268, encodeId=33c812122680a, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d6c75291303, createdName=14863d7cm33暂无昵称, createdTime=Mon Apr 18 19:24:08 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208858, encodeId=4e83120885850, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05de6574530, createdName=ms9000001201554124, createdTime=Tue Apr 05 22:57:51 CST 2022, time=2022-04-05, status=1, ipAttribution=)]
    2022-05-17 眼科芳

    受益

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1220566, encodeId=fc1f1220566ad, content=受益, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44565409552, createdName=眼科芳, createdTime=Tue May 17 23:11:35 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212268, encodeId=33c812122680a, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d6c75291303, createdName=14863d7cm33暂无昵称, createdTime=Mon Apr 18 19:24:08 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208858, encodeId=4e83120885850, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05de6574530, createdName=ms9000001201554124, createdTime=Tue Apr 05 22:57:51 CST 2022, time=2022-04-05, status=1, ipAttribution=)]
    2022-04-18 14863d7cm33暂无昵称

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1220566, encodeId=fc1f1220566ad, content=受益, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44565409552, createdName=眼科芳, createdTime=Tue May 17 23:11:35 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212268, encodeId=33c812122680a, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d6c75291303, createdName=14863d7cm33暂无昵称, createdTime=Mon Apr 18 19:24:08 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208858, encodeId=4e83120885850, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05de6574530, createdName=ms9000001201554124, createdTime=Tue Apr 05 22:57:51 CST 2022, time=2022-04-05, status=1, ipAttribution=)]
    2022-04-05 ms9000001201554124

    学习

    0

Baidu
map
Baidu
map
Baidu
map